<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37354691</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-3102</ISSN><JournalIssue CitedMedium="Internet"><Volume>139</Volume><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Placenta</Title><ISOAbbreviation>Placenta</ISOAbbreviation></Journal><ArticleTitle>Correlation of placental lesions in patients with systemic lupus erythematosus, antiphospholipid syndrome and non-criteria obstetric antiphospholipid syndrome and adverse perinatal outcomes.</ArticleTitle><Pagination><StartPage>92</StartPage><EndPage>98</EndPage><MedlinePgn>92-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.placenta.2023.06.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0143-4004(23)00148-0</ELocationID><Abstract><AbstractText Label="INTRODUCTION">We aimed to describe the pattern of placental injuries in women with systemic lupus erythematosus (SLE), antiphospholipid antibody syndrome (APS) and non-criteria obstetric APS (NC-OAPS), and to correlate the placental findings with the occurrence of adverse perinatal outcomes.</AbstractText><AbstractText Label="METHODS">The perinatal outcomes and placental findings of pregnancies of women with SLE, APS, and NC-OAPS and gestational-age matched healthy controls were analyzed and classified according to the 2015 Redline - Classification of placental lesions.</AbstractText><AbstractText Label="RESULTS">91 women with SLE, APS, and NC-OAPS and 91 controls were included. Mean values of placental weight differed between groups, being significantly lower in NC-OAPS and APS groups compared to controls. Furthermore, 14.3% of placentas in the APS group were under the 3rd percentile, which was significantly higher in comparison with other groups. Regarding histopathological placental findings, maternal-side malperfusion was significantly increased in APS (46.4%) compared to NC-OAPS (14.3%) and SLE (9.5%). Fetal-side maldevelopment was significantly increased in NC-OAPS (19.1%) compared to controls (1.1%) and SLE (2.4%). A significantly increased prevalence of adverse perinatal outcomes (APOs) was observed in all studied groups compared to healthy controls (controls 3.3%, SLE 52.4%, NC-OAPS 57.1%, APS 64.3%). Overall, both maternal (OR 6.8, 95%CI 2.1-22) and fetal-side (OR 4.1, 95%CI 1.3-13.5) lesions were significantly associated with APO. Maternal malperfusion and fetal maldevelopment were the lesions most strongly associated with APOs.</AbstractText><AbstractText Label="DISCUSSION">Pregnant women with SLE, APS, or NC-OAPS showed a different pattern of histopathological findings. Compared to controls, SLE, APS, and NC-OAPS conferred an increased risk of APOs that was strongly associated with placental maternal-side malperfusion and fetal-side maldevelopment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castellanos Gutierrez</LastName><ForeName>Aleida Susana</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Cl&#xed;nic and Hospital Sant Joan de D&#xe9;u. Universitat de Barcelona), Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer (IDIBAPS), Spain; Placenta Lab, Department of Obstetrics, Jena University Hospital, 07747, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueras</LastName><ForeName>Francesc</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Cl&#xed;nic and Hospital Sant Joan de D&#xe9;u. Universitat de Barcelona), Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer (IDIBAPS), Spain; Centre for Biomedical Research on Rare Diseases (CIBER-ER), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espinosa</LastName><ForeName>Gerard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Autoimmune Diseases, Hospital Cl&#xed;nic Barcelona, Universitat de Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youssef</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Cl&#xed;nic and Hospital Sant Joan de D&#xe9;u. Universitat de Barcelona), Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer (IDIBAPS), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crispi</LastName><ForeName>F&#xe0;tima</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Cl&#xed;nic and Hospital Sant Joan de D&#xe9;u. Universitat de Barcelona), Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer (IDIBAPS), Spain; Centre for Biomedical Research on Rare Diseases (CIBER-ER), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santana</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Cl&#xed;nic and Hospital Sant Joan de D&#xe9;u. Universitat de Barcelona), Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer (IDIBAPS), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadal</LastName><ForeName>Alfons</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Hospital Clinic Barcelona, Universitat de Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ba&#xf1;os</LastName><ForeName>N&#xfa;ria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Cl&#xed;nic and Hospital Sant Joan de D&#xe9;u. Universitat de Barcelona), Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer (IDIBAPS), Spain. Electronic address: nbanos@clinic.cat.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Placenta</MedlineTA><NlmUniqueID>8006349</NlmUniqueID><ISSNLinking>0143-4004</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010920" MajorTopicYN="N">Placenta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011248" MajorTopicYN="Y">Pregnancy Complications</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse perinatal outcome</Keyword><Keyword MajorTopicYN="N">Antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">Autoimmune disease</Keyword><Keyword MajorTopicYN="N">Placental histopathology</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>25</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>24</Day><Hour>18</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37354691</ArticleId><ArticleId IdType="doi">10.1016/j.placenta.2023.06.013</ArticleId><ArticleId IdType="pii">S0143-4004(23)00148-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>